BACKGROUND: We have previously shown that the receptor tyrosine kinases, KIT and PDGFRalpha, are expressed on ESFT cell lines, and that imatinib induces dose-dependent apoptosis (1). We conducted a Phase II trial to evaluate the effectiveness of imatinib for patients with recurrent ESFT or DSRCT expressing KIT and/or PDGFRalpha. PATIENTS AND METHODS: Patients were selected for tumor immunohisto-chemical expression > or =2+/4+ for KIT or PDGFRalpha. Imatinib was administered orally 400 mg twice/day for 28 days/course. Primary endpoint was response. RESULTS: Seven patients were enrolled and evaluated. One patient with 3+/4+ PDGFRalpha and 3+/4+ KIT expression had a partial response through 8 courses. 4 patients had progression after 1 cycle. Two patients were not evaluable due to one early death and one refusing treatment. CONCLUSION: This study intended to enrich for molecular factors that potentially predict response. Given the poor prognosis with recurrent ESFT, further studies with other novel KIT and PDGFRalpha inhibitors are needed.
BACKGROUND: We have previously shown that the receptor tyrosine kinases, KIT and PDGFRalpha, are expressed on ESFT cell lines, and that imatinib induces dose-dependent apoptosis (1). We conducted a Phase II trial to evaluate the effectiveness of imatinib for patients with recurrent ESFT or DSRCT expressing KIT and/or PDGFRalpha. PATIENTS AND METHODS: Patients were selected for tumor immunohisto-chemical expression > or =2+/4+ for KIT or PDGFRalpha. Imatinib was administered orally 400 mg twice/day for 28 days/course. Primary endpoint was response. RESULTS: Seven patients were enrolled and evaluated. One patient with 3+/4+ PDGFRalpha and 3+/4+ KIT expression had a partial response through 8 courses. 4 patients had progression after 1 cycle. Two patients were not evaluable due to one early death and one refusing treatment. CONCLUSION: This study intended to enrich for molecular factors that potentially predict response. Given the poor prognosis with recurrent ESFT, further studies with other novel KIT and PDGFRalpha inhibitors are needed.
Authors: Vivek Subbiah; Salah-Eddine Lamhamedi-Cherradi; Branko Cuglievan; Brian A Menegaz; Pamela Camacho; Winston Huh; Vandhana Ramamoorthy; Pete M Anderson; Raphael E Pollock; Dina C Lev; Wei Qiao; Mary Frances McAleer; Robert S Benjamin; Shreyaskumar Patel; Cynthia E Herzog; Najat C Daw; Barry W Feig; Alexander J Lazar; Andrea Hayes-Jordan; Joseph A Ludwig Journal: Clin Cancer Res Date: 2018-06-05 Impact factor: 12.531
Authors: Mónica Enguita-Germán; Mikel Gurrea; Paula Schiapparelli; Thant S Zhu; Jessica G Crowley; Lisa L Hamm; Mark A Costello; Xiaobing He; Caroline E Talsma; Callie G Flack; Shawn L Hervey-Jumper; Jason A Heth; Karin M Muraszko; Juan A Rey; Xing Fan; Javier S Castresana Journal: J Neurooncol Date: 2010-09-19 Impact factor: 4.130
Authors: Florencia Cidre-Aranaz; Sarah Watson; James F Amatruda; Takuro Nakamura; Olivier Delattre; Enrique de Alava; Uta Dirksen; Thomas G P Grünewald Journal: Nat Rev Dis Primers Date: 2022-10-06 Impact factor: 65.038
Authors: Xiang Nan; Jiang Wang; Hao Cheng; Zheng Yin; Jianting Sheng; Bensheng Qiu; Ching C Lau; Jason T Yustein; Hong Zhao; Stephen T C Wong Journal: Cancer Lett Date: 2019-10-28 Impact factor: 8.679
Authors: Jennifer Dallas; Iman Imanirad; Rajiv Rajani; Roi Dagan; Sukanthini Subbiah; Rebecca Gaa; Wayne A Dwarica; Alison M Ivey; Robert A Zlotecki; Robert Malyapa; Danny J Indelicato; Mark T Scarborough; John D Reith; C Parker Gibbs; Long H Dang Journal: J Med Case Rep Date: 2012-01-30